1007591-49-2

Upstream product

• 34250-16-3 3-oxocyclopent-1-ene-1-carbonitrile 
• 368-63-8 (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol 
• 10481-34-2 2-bromo-2-cyclopenten-1-one 
• 930-30-3 cyclopent-2-enone 
• 1007592-12-2 C₁₇H₁₆F₆O₂ 
• 352-13-6 4-flourophenylmagnesium bromide 
• 1007591-98-1 C₁₆H₁₃F₆NO 
• 1007591-93-6 C₁₇H₁₃NO₂ 
• 1007591-88-9 (S)-3-hydroxycyclopent-1-enecarbonitrile 
• 1493-23-8 (4-fluorophenyl)lithium 
• 1007592-25-7 C₂₃H₂₁F₇O₂ 

Downstream Products

• 1007593-13-6 C₂₃H₂₀ClF₇O₂ 
• 1007593-46-5 C₂₃H₂₀F₇IO₂ 
• 1007593-16-9 C₄₁H₃₆F₇NO₆ 
• 871589-86-5 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-3-benzyloxycarboxylamino-3-methylpyrrolidin-2-one 

Relevant academic research and scientific papers

Enantioselective, biocatalytic reduction of 3-substituted cyclopentenones: Application to the asymmetric synthesis of an hNK-1 receptor antagonist

A convergent and enantioselective route to the hNK-1 receptor antagonist (1) is described, which sets all six stereogenic centers with high diastereoselectivity and delivers 1 in only 11 steps and 23% overall yield. The process was enabled by the developm

PROCESS FOR MAKING LACTAM TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to a process for preparing certain α,α disubstituted γ-lactam derivatives that are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful i